Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosis

Table 2 Higher anti-CXCR3 and anti-CXCR4 antibody levels are associated with stable lung function parameters

Parameter	Patients above cut-off (%)		Patients below cut-off (%)		p values	Number of analyzed patients	Hazard ratios
Parameter	Deterioration ≥ 10%	No deterioration	Deterioration ≥ 10%	No deterioration	p values	Number of analyzed patients	Hazard ratios
Anti-CXCR3 antibodies
FVC (%)	25.0	75.0	59.3	40.7	≤ 0.01	59	0.32
FEV1 (%)	23.5	76.5	71.1	28.9	≤ 0.001	72	0.22
DLCO-SB (%)	36.4	63.6	63.6	36.4	≤ 0.05	55	0.47
DLCO/VA (%)	42.4	57.6	70.4	29.6	≤ 0.05	60	0.38
Anti-CXCR4 antibodies
FVC (%)	22.2	77.8	70.0	30.0	≤ 0.001	47	0.2
FEV1 (%)	33.3	66.7	78.6	21.4	≤ 0.001	61	0.27
TLC (%)	33.3	66.7	64.7	35.3	≤ 0.05	44	0.33
DLCO-SB (%)	43.3	56.7	75.0	25.0	≤ 0.05	46	0.46
DLCO/VA (%)	39.4	60.6	82.4	17.6	≤ 0.001	50	0.24

Patients with antibody levels above and below cut-off, with and without deterioration in forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), total lung capacity (TLC), the diffusing capacity for carbon monoxide (DLCO) measured by a single breath (DLCO-SB), and DLCO/VA within 3 years, p values (log-rank test) as well as number of analyzed patients are shown
Hazard ratios derived from the Cox proportional hazards model highlight the relationship between deterioration in lung function parameters and anti-CXCR3/anti-CXCR4 antibody levels